These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2042796)

  • 21. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon.
    Marasini B; Biondi ML; Mollica R
    Eur J Clin Pharmacol; 1990; 39(3):289-90. PubMed ID: 2257869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Raynaud's phenomenon: effects of terazosin].
    Paterna S; Pinto A; Arrostuto A; Cannavò MG; Di Pasquale P; Cottone C; Licata G
    Minerva Cardioangiol; 1997 May; 45(5):215-21. PubMed ID: 9273472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Int Angiol; 1987; 6(3):313-22. PubMed ID: 3329207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
    Brouwer RM; Wenting GJ; Man in't Veld AJ; Schalekamp MA
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S26-31. PubMed ID: 2446064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.
    Baart de la Faille H; van Weelden H; Banga JD; van Kesteren RG
    Arch Dermatol Res; 1986; 279(1):3-7. PubMed ID: 3545103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Reserpine administration by retrograde intravenous route in patients with Raynaud's phenomenon].
    Acevedo A; Arinoviche R; Palma A; Olea E; Guzmán G; Arriagada M; Grisanti M; Testar R
    Rev Med Chil; 1982 Nov; 110(11):1063-5. PubMed ID: 7184095
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.
    van Oene JC
    Drugs; 1988; 36 Suppl 1():148-51. PubMed ID: 3240729
    [No Abstract]   [Full Text] [Related]  

  • 29. [Local administration of cerebrolysin in Raynaud's disease in a 2-year-old child].
    Osipenko TN; Skvortsov IA; Korshunov SV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(8):100-3. PubMed ID: 1661499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of Raynaud's syndrome with ketanserin. Clinical, biological and hemodynamic aspects].
    Bellucci S; Kedra AW; Naccache-Herman V; Cambau E; Tobelem G; Caen JP
    Presse Med; 1987 Jul 11-18; 16(27):1335. PubMed ID: 2956601
    [No Abstract]   [Full Text] [Related]  

  • 31. [The therapy of Raynaud's phenomenon].
    Di Giacinto G
    Clin Ter; 1993 Feb; 142(2):161-74. PubMed ID: 8472530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of ketanserin in the therapy of Raynaud's phenomenon: thermometric data.
    Arosio E; Montesi G; Zannoni M; Perbellini L; Paluani F; Lechi A
    Angiology; 1991 May; 42(5):408-13. PubMed ID: 2035893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pain relief following post-ganglionic sympathetic blockade with I.V. guanethidine.
    Glynn CJ; Basedow RW; Walsh JA
    Br J Anaesth; 1981 Dec; 53(12):1297-302. PubMed ID: 7317248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis.
    Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G
    Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
    van de Wal HJ; Wijn PF; van Lier HJ; Skotnicki SH
    Microcirc Endothelium Lymphatics; 1985; 2(6):657-85. PubMed ID: 2942753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon.
    Seibold JR; Terregino CA
    J Rheumatol; 1986 Apr; 13(2):337-40. PubMed ID: 2941573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of Raynaud's phenomenon].
    Lazareth I
    Ann Dermatol Venereol; 1987; 114(8):1035-8. PubMed ID: 2892456
    [No Abstract]   [Full Text] [Related]  

  • 39. [The use of capillary videomicroscopy in the therapeutic assessment of acral vasospastic phenomena: microcirculatory effect of ketanserin and nifedipine].
    Gasser P
    Schweiz Rundsch Med Prax; 1994 Apr; 83(17):511-4. PubMed ID: 8191194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raynaud's phenomenon.
    Belch JJ
    Curr Opin Rheumatol; 1989 Dec; 1(4):490-8. PubMed ID: 2702051
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.